Following U.S. Stocks were among the “Top Gainers” during Friday’s trade: Rigel Pharmaceuticals, Inc (NASDAQ:RIGL), ArQule, Inc. (NASDAQ:ARQL), Advaxis, Inc (NASDAQ:ADXS), FuelCell Energy Inc (NASDAQ:FCEL)

Their insights are depicted underneath:

Rigel Pharmaceuticals, Inc (NASDAQ:RIGL)’s shares picked up 7.88%, and closed at $3.56.

According to PRNewswire, Rigel Pharmaceuticals, Inc. (RIGL), stated financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, Rigel stated a net loss of $22.3 million, or $0.25 per share, contrast to a net loss of $16.9 million, or $0.19 per share, in the fourth quarter of 2013. Weighted average shares outstanding for the fourth quarters of 2014 and 2013 were 87.8 million and 87.4 million, respectively.

Contract proceeds from collaborations of $8.3 million and $5.8 million in the fourth quarters of 2014 and 2013, respectively, were comprised of non-refundable payments earned from AstraZeneca AB (AZ) as a result of its continued development of R256 in asthma.

Rigel stated total costs and expenses of $30.6 million in the fourth quarter of 2014, contrast to $22.7 million in the fourth quarter of 2013. The raise in costs and expenses was primarily due to a charge related to the loss on executing a sublease during the quarter, in addition to an raise in stock-based compensation expense and severance costs related to the retirement of Rigel’s former chief executive officer, partially offset by the decrease in research and development costs. The loss on the sublease is determined based on the present value of the excess of Rigel’s future remaining payments to its landlord through January 2018 associated with the applicable subleased space over its contractual sublease revenue from its subtenant over the term of the sublease contract Rigel executed in December 2014. The research and development costs in the fourth quarter of 2013 were comprised of certain non-recurring development costs related to the transfer of fostamatinib raw materials from AZ. Research and development costs reduced in 2014 due to the completion of a Phase 2 clinical study with R348 in dry eye and the discontinuation of a Phase 1 clinical study with R118, Rigel’s indirect AMPK activator program.

For the year ended December 31, 2014, Rigel stated contract proceeds from collaborations of $8.3 million and a net loss of $90.9 million, or $1.04 per basic and diluted share, contrast to contract proceeds from collaborations of $7.2 million and a net loss of $89.0 million, or $1.02 per basic and diluted share, in 2013. Contract proceeds from collaborations in 2014 and 2013 comprised of $8.3 million and $5.8 million, respectively, of non-refundable payments earned from AZ, and a non-refundable payment of $1.4 million in 2013 from Daiichi Sankyo related to their investigational new drug application filing for an oncology compound.

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development corporation that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. Rigel’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.

ArQule, Inc. (NASDAQ:ARQL), raised 7.35%, and closed at $2.19, hitting new 52-week high of $2.24.

According to BUSINESS WIRE. ArQule Inc. (ARQL), declared its financial results for the year and the fourth quarter ended December 31, 2014. The Corporation stated a net loss of $23,391,000 or $0.37 per share, for the year ended December 31, 2014, contrast with a net loss of $24,600,000 or $0.39 per share, for the year ended December 31, 2013. For the quarter ended December 31, 2014, the Corporation stated a net loss of $3,512,000 or $0.06 per share, contrast with net loss of $5,956,000 or $0.10 per share, for the quarter ended December 31, 2013.

At December 31, 2014, the Corporation had a total of about $61,266,000 in cash and marketable securities.

Operational Milestones:

Tivantinib (ARQ 197):

• Acceleration of the predictable timeline to completion of patient accrual in the Phase 3 METIV-HCC trial in hepatocellular carcinoma to the end of 2015 based on timely recruitment of patients at more than 100 clinical sites worldwide during 2014;
• Initiation of the Phase 3 JET-HCC trial in Japan by Kyowa Hakko Kirin, the Corporation’s partner in Asian territories;
• Positive results from a randomized, double-blind, placebo-controlled Phase 2 trial with tivantinib as a single agent in prostate cancer, sponsored by the National Institutes of Health (NIH);
• Seven presentations of tivantinib across multiple diseases and therapeutic combinations at the 2014 ASCO Annual Meeting.

Pipeline:

• Expansion of Phase 1a clinical testing with ARQ 092, ARQ 087 and ARQ 761 into tumor-enriched and biomarker-defined Phase 1b testing;
• Signing of an contract with the NIH to initiate the clinical development of ARQ 092 in Proteus Syndrome, the first non-oncology rare disease indication to be pursued with this compound;
• Presentation of pre-clinical data with ARQ 092 at the American Society of Human Genetics by researchers from the NIH demonstrating rapid shutdown of AKT signaling and a reduction in the viability of Proteus Syndrome cells treated with ARQ 092;
• Eight presentations of clinical and pre-clinical data on ARQ 092, ARQ 087 and ARQ 761 at the 26th EORTC-NCI-AACR Symposium.

ArQule is a biotechnology corporation engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Corporation’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase.

Advaxis, Inc (NASDAQ:ADXS), enhanced 7.21%, and closed at $11.90.

According to GLOBE NEWSWIRE, Advaxis, Inc. (ADXS), a clinical-stage biotechnology corporation developing cancer immunotherapies, declared recently that Daniel J. O’Connor, President and Chief Executive Officer of Advaxis, will present at the 27th Annual ROTH Conference being held March 8-11, 2015, at the Ritz-Carlton Hotel in Laguna Niguel, CA.

Advaxis, Inc., a clinical stage biotechnology corporation, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States.

FuelCell Energy Inc (NASDAQ:FCEL), rose 6.82%, and closed at $1.14.

According to GLOBE NEWSWIRE, FuelCell Energy Inc. (FCEL), a global leader in the design, manufacture, operation and service of ultra-clean, efficient and reliable fuel cell power plants, recently declared the continued progress in the commercialization of an affordable and efficient carbon capture solution utilizing fuel cells, following thousands of hours of testing with simulated flue gas of a coal-fired power plant. In addition to this evaluation under a U.S. Department of Energy (DOE) contract, the program comprised of a detailed design and cost analysis for fuel cell applications capturing carbon dioxide (CO2) from large scale coal-fired power plants. Results of this study support cost targets below the U.S. Department of Energy threshold of $40/ton. An additional benefit demonstrated is tolerance levels and clean up requirements for the impurities in coal plant exhaust, in addition to the ability to destroy about 70 percent of smog-producing nitrogen oxide (NOx).

In addition to this progress for coal-fired applications, testing is being conducted with private funding for the evaluation of fuel cells for capturing CO2 from natural gas fired power plants. Results to date are supporting the viability and cost targets for gas-fired power plants and exhaust sources.

Direct FuelCell(R) power plants are generating ultra-clean, efficient and reliable power at more than 50 locations worldwide. With more than 300 megawatts of power generation capacity installed or in backlog, FuelCell Energy is a global leader in providing ultra-clean baseload distributed generation to utilities, industrial operations, universities, municipal water treatment facilities, government installations and other customers around the world.